Esser et al. reported that the combinational treatment of CIK cells with anti-CD30 mAb Brentuximab Vedotin (SGN-35) achieved better efficacy in CD30+ lymphoma, and SGN-35 did not affect the function of CIK cells (81). The gene discussed is TNFRSF8; the disease is lymphoma.